The discovery of CCR3/H1 dual antagonists with reduced hERG risk-Reference-Cited by-同舟云学术

The discovery of CCR3/H1 dual antagonists with reduced hERG risk

Published:2012-11 Issue:21 Volume:22 Page:6688-6693
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Bahl Ash,Barton Patrick,Bowers Keith,Brough Steven,Evans Richard,Luckhurst Christopher A.,Mochel Tobias,Perry Matthew W.D.,Rigby Aaron,Riley Robert J.,Sanganee Hitesh,Sisson Adam,Springthorpe Brian

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference36 articles.

1. Asthma, Allergy and Chemokines

2. Chemokines and Their Receptors in Chronic Pulmonary Disease

3. Bahl A, Springthorpe B and Riley R (2010). Chemokine CCR3 antagonists. In: New Drugs and Targets for Asthma and COPD. by Hansel T. T., Barnes P. J. (Eds.), series edited Bolliger C. T. (Ed.), Prog. R. Res., 2010,39, 153.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability;Journal of Medicinal Chemistry;2022-01-27

2. Applications of fluorine-containing amino acids for drug design;European Journal of Medicinal Chemistry;2020-01

3. Application of Sulfonyl in Drug Design;Chinese Journal of Organic Chemistry;2016

4. Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: Insights from a receptor model;Bioorganic & Medicinal Chemistry Letters;2015-01

5. Early identification of hERG liability in drug discovery programs by automated patch clamp;Frontiers in Pharmacology;2014-09-02